Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018, 378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
Advertisement
Articles by Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018, 378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
Advertisement
Latest Updated Articles
- Study Summary: Use of Enzalutamide for High-Risk, Nonmetastatic, Castration-Resistant Prostate Cancer (PROSPER)
Published: November 9th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
3
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
4
Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial
5
